Eli Lilly CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder
- Conditions
- Bipolar Disorder
- Interventions
- First Posted Date
- 2005-08-11
- Last Posted Date
- 2010-12-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 224
- Registration Number
- NCT00129220
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan
Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2005-08-08
- Last Posted Date
- 2018-03-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 385
- Registration Number
- NCT00127634
- Locations
- 🇮🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Noida, India
🇭🇺For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hrs, EST), or speak with your personal physician., Szeged, Hungary
PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension
- First Posted Date
- 2005-08-02
- Last Posted Date
- 2008-02-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 406
- Registration Number
- NCT00125918
- Locations
- 🇮🇹
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bergamo, Italy
A Study of Duloxetine in the Treatment of Fibromyalgia
- Conditions
- Fibromyalgia
- First Posted Date
- 2005-08-02
- Last Posted Date
- 2007-05-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 320
- Registration Number
- NCT00125892
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday - Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Saskatoon, Saskatchewan, Canada
🇲🇽For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday - Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician, Morelia, Michoacan, Mexico
🇨🇳For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday - Friday from 9:00 AM to 5:00PM Eastern Time (UTC/GMT - 5 hours , EST) or speak with your personal physician, Kaohsiung, Taiwan
Duloxetine Compared With Placebo in Patients With Generalized Anxiety Disorder
- Conditions
- Anxiety Disorders
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2007-11-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 480
- Registration Number
- NCT00122824
- Locations
- 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Uppsala, Sweden
A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder
- Conditions
- Anxiety Disorders
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2007-11-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 480
- Registration Number
- NCT00122850
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Seattle, Washington, United States
A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder
- Conditions
- Anxiety Disorder
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2007-10-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 560
- Registration Number
- NCT00122837
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Glasgow, Scotland, United Kingdom
Duloxetine Compared With Placebo in the Prevention of Relapse in Generalized Anxiety Disorder
- Conditions
- Anxiety Disorders
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2007-08-31
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 380
- Registration Number
- NCT00122863
- Locations
- 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ponce, Puerto Rico
🇩🇪For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hildesheim, Germany
A Study in People With Abnormal Fat Levels in the Blood
- Conditions
- Dyslipidemia
- First Posted Date
- 2005-06-30
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 300
- Registration Number
- NCT00116519
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Wenatchee, Washington, United States
Olanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder
- Conditions
- SchizophreniaBipolar Disorder
- First Posted Date
- 2005-06-10
- Last Posted Date
- 2007-11-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 100
- Registration Number
- NCT00113594
- Locations
- 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Moscow, Russian Federation